NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 91.5

Change

+0.46 (+0.51)%

Market Cap

USD 0.67B

Volume

0.85M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 41.47B
ICLR ICON PLC

N/A

USD 25.49B
ILMN Illumina Inc

N/A

USD 19.47B
MEDP Medpace Holdings Inc

N/A

USD 12.27B
EXAS EXACT Sciences Corporation

N/A

USD 10.68B
RDNT RadNet Inc

N/A

USD 3.57B
SHC Sotera Health Co

N/A

USD 3.10B
OLK Olink Holding AB ADR

N/A

USD 2.72B
NEOG Neogen Corporation

N/A

USD 2.63B
GH Guardant Health Inc

N/A

USD 1.96B

ETFs Containing NTRA

GNOG:LSE Global X Genomics & Biote.. 7.69 % 0.00 %

N/A

USD 8.88M
GN0M:XETRA Global X Genomics & Biote.. 7.23 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.34 % 0.00 %

N/A

USD 6.73M
EKG First Trust Nasdaq Lux Di.. 4.32 % 0.00 %

N/A

USD 2.33M
CURE:XETRA VanEck Genomics and Healt.. 3.33 % 0.00 %

N/A

USD 6.89M
PTH Invesco DWA Healthcare Mo.. 2.83 % 0.60 %

N/A

USD 0.13B
XMLH:F Legal & General Ucits Etf.. 2.29 % 0.00 %

N/A

USD 0.08B
DOCT:SW L&G Healthcare Breakthrou.. 2.29 % 0.00 %

N/A

USD 0.08B
WDNA 2.28 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.21 % 0.00 %

N/A

USD 6.95M
WDNA:LSE WisdomTree BioRevolution .. 2.21 % 0.00 %

N/A

USD 2.65M
WRNA:XETRA WisdomTree BioRevolution .. 2.10 % 0.00 %

N/A

USD 2.77M
DRDR:LSE iShares Healthcare Innova.. 1.81 % 0.00 %

N/A

USD 1.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.81 % 0.00 %

N/A

USD 0.08B
DOCT:LSE L&G Healthcare Breakthrou.. 1.81 % 0.00 %

N/A

USD 0.08B
WELL:LSE Hanetf Icav - Han-Gins He.. 1.66 % 0.00 %

N/A

USD 0.02B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.58 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.43 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.43 % 0.00 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

USD 1.08B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

N/A

USD 0.33B
JKJ iShares Morningstar Small.. 0.00 % 0.25 %

N/A

USD 0.21B
JKK iShares Morningstar Small.. 0.00 % 0.30 %

N/A

USD 0.52B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.92B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD 0.04B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

N/A

USD 17.08B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

USD 7.05B
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

N/A

USD 3.29B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
IS0R:XETRA iShares High Yield Corpor.. 0.00 % 0.00 %

N/A

USD 2.71B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.07B
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

N/A

USD 0.03B
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.52B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 46.07% 95% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.07% 95% A 91% A-
Trailing 12 Months  
Capital Gain 83.85% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.85% 91% A- 92% A
Trailing 5 Years  
Capital Gain 379.31% 97% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 379.31% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 44.91% 84% B 90% A-
Dividend Return 44.91% 84% B 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 87.21% 34% F 18% F
Risk Adjusted Return 51.49% 88% B+ 82% B
Market Capitalization 0.67B 90% A- 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 14.49 12% 7%
Price / Cash Flow Ratio -45.14 90% 93%
Price/Free Cash Flow Ratio -26.78 94% 92%
Management Effectiveness  
Return on Equity -59.11% 46% 28%
Return on Invested Capital -40.41% 50% 26%
Return on Assets -19.67% 46% 25%
Debt to Equity Ratio 36.97% 43% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector